ResMed Inc.’s Stock Price Drops to $231.17, Experiencing a 2.57% Decline

ResMed Inc. (RMD)

231.17 USD -6.10 (-2.57%) Volume: 1.15M

ResMed Inc.’s stock price stands at 231.17 USD, experiencing a drop of -2.57% this trading session with a trading volume of 1.15M, despite boasting a robust YTD increase of +32.83%, illustrating the stock’s strong performance and potential for investors.

Latest developments on ResMed Inc.

ResMed Inc. (NYSE:RMD) saw its stock price movements today as Principal Financial Group Inc. bought shares, indicating investor confidence in the company. Despite a gap down in shares, ResMed remains a top growth stock for the long-term, with potential bearish signals from insiders disposing of stock. The recent approval of Eli Lilly’s obesity drug for sleep apnea raises questions about potential competition for ResMed in the market. Overall, the stock is closely watched by investors for its growth potential and market dynamics.

ResMed Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma are bullish on ResMed Inc, a company focused on sleep health and breathing devices. In their report “ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! – Major Drivers”, they highlight the company’s strong start in Q1 Fiscal Year 2025, with an 11% revenue increase driven by demand for various products and software offerings. Baptista Research aims to assess factors influencing the company’s stock price and conduct an independent valuation using the Discounted Cash Flow (DCF) methodology.

In another report by Baptista Research titled “ResMed Inc.: A Story Of Increased Market Penetration and New Patient Acquisition! – Major Drivers”, analysts delve into ResMed’s fourth quarter results for fiscal year 2024. The company showcased robust growth, achieving a 9% revenue increase year-over-year totaling $1.22 billion for the quarter. With a focus on innovations in sleep apnea, digital health solutions, and home medical equipment software, ResMed continues to attract new customers and expand its market presence, garnering positive sentiment from analysts on Smartkarma.

A look at ResMed Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

ResMed Inc. has a mixed outlook based on the Smartkarma Smart Scores. While the company scores well in growth and momentum, with scores of 4 each, it falls short in value and resilience, with scores of 2 each. The dividend score stands at a moderate 3. This suggests that while ResMed Inc. shows promising signs of growth and momentum, investors may need to consider the company’s value and resilience factors for a more comprehensive long-term investment strategy.

ResMed Inc. is a company that specializes in medical equipment for the treatment of sleep disordered breathing. With a focus on diagnostic and treatment devices, the company operates globally through its subsidiaries and independent distributors. Despite facing challenges in value and resilience, the company’s strong growth and momentum scores indicate potential opportunities for future development and expansion in the medical equipment industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma